US: Pharmaceuticals
More
-
Good morning all. Here's what's happening on our finals leaderboard with three days of trading left. Nancy Beaumont--pictured left--remains in first place--even with losing almost $30K on Pacific Sunwear Tuesday. And Serge Amelyan moves back into 2nd on an almost $5K gain on Vanda Pharma, and helped by Steven Lee's $76K loss on Neurochem.
-
Women looking for a simple way to avoid their menstrual period could soon have access to the first birth control pill designed to let women suppress monthly bleeding indefinitely.
-
The company built by the world's richest man takes on the world's largest democracy, and it's a case of cyber culture clash. India-based itVAR News (an IT website) says Microsoft is billing computer retailers in the town of Gujarat thousands of dollars, accusing them of installing pirated Windows software.The retailers have responded with a strike, a boycott and general outrage, though no one appears to be denying the accusations. One Indian retailer put it this way, "Since we are not charging anything extra for installing the software, it means that we are actually not trading in pirated software. For us, this is just a 'sewa' (selfless act) that we are offering to our customers. Besides, the pricing of their operating systems is way too high for Indian markets."
-
So, let's start with GlaxoSmithKline's Avandia. The stock is rebounding a little bit today after the pummeling it took yesterday. Once again, the New England Journal of Medicine study saw an "embargo break" by another media outlet. That means the news hit in the middle of the trading day yesterday, catching just about everyone by surprise. The embargo was supposed to have lifted at 5 p.m. ET yesterday, which would have given all of the stakeholders -- chiefly Glaxo -- the ability to issue their prepared press releases at the same time.
-
So, who's leading the pack as the CNBC Million Dollar Portfolio Challenge heads into its final days (only four left)? Well, we have the up to date standings along with a video clip with the ins and outs. We also have the leaders of the Second Chance Showdown. This is for the contestants who didn't make it into the finals--but can win a Sony Home Theatre Entertainment system. The winner in each category will have to come up with the portfolio with the largest value.
-
Asset sales and earnings reports catalyzed the most actively traded stocks on Tuesday.
-
Good morning. Chinese gaming stocks are in the spotlight Monday as The9 propelled Nancy Beaumont to the top of the pack on its 10.31% gain. The9 was up on the news that Electronic Arts agreed to buy a $167M stake in the company, and also licensed a soccer game to The9. Steven Lee managed to hold onto second even though he was all in cash after Friday's trading. He has now gone all-in on Neurochem.
-
GlaxoSmithKline's widely prescribed diabetes drug Avandia is linked to a greater risk of heart attack and possibly death, a new scientific analysis revealed, and the U.S. government issued a safety alert.
-
Shares of drug developers Wyeth and Elan jumped Monday after the companies said they plan on asking for approval to move their Alzheimer's treatment candidate bapineuzumab into late-stage studies.
-
M&A news and drug trial updates provided some of the catalysts behind the most actively traded stocks on Monday.
-
It sits there in front of you: a plate filled to the overflow point with chili -- and under it, two cheeseburger patties, fried potatoes and one egg, over easy.What are you about to do?
-
Here's our contest stock report for both the finals and Second Chance Showdown. Acxiom proved to be a winner for several finalsts--and you can see why. It was up 18%. But those who had ADS did even better as that stock was up 24% on news of a merger. Weak earnings took a toll on the worst performing stocks--while the most active and widely held reamined the same.
-
Cramer answers viewers' questions about Nutrisystem and Syneron. Plus, praise for the men and women in uniform serving in Iraq.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
Over the past couple of days, a couple of analyst reports have come into my inbox regarding the results of the so-called "CRYSTAL" study of ImClone's Erbitux on metastatic colorectal cancer. ImClone shares Erbitux with Bristol-Myers Squibb. The drug is approved for colon and head and neck cancers, but they're testing it on other tumor types. CRYSTAL is an acronym, but you won't believe how they stretched to create it: Cetuximab combined with iRinotecan in first line therapY for metaSTatic colorectAL cancer. Which came first? The acronym or the study description? Anyway, I digress. Crazy clinical trial acronyms are for another day, another blog entry.
-
This week Cramer is doing a series on CEOs, the best of the best when it comes to company turnarounds. These five executives have turned their once-dead franchises into living, thriving businesses. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
Comedienne and writer Judy Gold ends Trading with the Stars on a high note--with the same positive attitude she says she had throughout the contest. Good for her--and her charity, the Anti-defamation League which will receive $5,000 for Judy's participation. She did come in fifth place--but if you look at the leaderboard on the video below--that turns into first place on the second slide you'll see. So--we'll call her the first of the non winners. ( a stretch but we're trying to be as generous as Judy was with her time.)Thanks Judy--you're as good as gold!
-
M&A news and quarterly updates provided some of the catalysts behind the most actively traded stocks on Monday.
-
The U.S. Supreme Court said it would not hear an appeal by drug maker Amgen that centers on how much leeway appeals courts should have in overruling the findings of lower courts in patent cases.
-
German drug maker Merck announced that it is selling its generic drug business to Mylan Laboratories for $6.6 billion.
-
A new study says if a drug is quickly developed that delays the onset of Alzheimer's Disease it would save the U.S. economy trillions of dollars.